Cite
CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells.
MLA
Mintz, Rachel L., et al. “CRISPR/Cas9‐mediated Mutagenesis to Validate the Synergy between PARP1 Inhibition and Chemotherapy in BRCA1‐mutated Breast Cancer Cells.” Bioengineering & Translational Medicine, vol. 5, no. 1, Jan. 2020, p. N.PAG. EBSCOhost, https://doi.org/10.1002/btm2.10152.
APA
Mintz, R. L., Lao, Y., Chi, C., He, S., Li, M., Quek, C. H., Shao, D., Chen, B., Han, J., Wang, S., & Leong, K. W. (2020). CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells. Bioengineering & Translational Medicine, 5(1), N.PAG. https://doi.org/10.1002/btm2.10152
Chicago
Mintz, Rachel L., Yeh‐Hsing Lao, Chun‐Wei Chi, Siyu He, Mingqiang Li, Chai Hoon Quek, Dan Shao, et al. 2020. “CRISPR/Cas9‐mediated Mutagenesis to Validate the Synergy between PARP1 Inhibition and Chemotherapy in BRCA1‐mutated Breast Cancer Cells.” Bioengineering & Translational Medicine 5 (1): N.PAG. doi:10.1002/btm2.10152.